AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05707234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam sedation
Description: During the procedure, the patient in the control group receives pharmacological sedation, which is the standard of care currently practiced. Such sedation allows intraoperative anxiolysis, which is constantly required by patients in order to dissociate from their surroundings. Recall that total knee replacement surgery is extremely noisy, and the surrounding environment is itself an anxiety-provoking factor for the patient. Light to moderate, intraoperative sedation is carried out by intermittent boluses of midazolam 1 mg IV. Boluses are given every 5 minutes until a sedation level of -2 or -3 on the RASS (Richmond Agitation-Sedation Scale) scale is reached.
Study NCT06659523 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPS supplement intervention
Description: 31 healthy individuals, male and female, were recruted at one family health unit, and randomly assigned to the intervention group, and were given for 12 weeks of one daily dose of 1.5 g powdered capsules of EPS.
Study NCT06659523 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 29 healthy individuals, male and female, were recruted at one family health unit, and randomly assigned to the placebo group, and were given for 12 weeks of one daily dose of placebo.
Study NCT05909189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LEADing Dementia End-of-Life Planning Conversations
Description: The LEAD Intervention is self-administered and delivered through an interactive, web-based platform designed according to recommended functionalities and user-designed principles. Through three distinct modules, the LEAD Intervention will facilitate the advance care planning processes of 1) defining care recipients' values and preferences for care, 2) developing advance care planning congruence within the pair, or a shared understanding of the care recipient's values and preferences, through conversation(s), and 3) encouraging ongoing advance care planning conversation and documentation that can be shared beyond the pair. All modules will include video tutorials to introduce the goals and tasks as well as provide interactive resources to provide support and education relevant to the content of each module. The three modules are intended to be followed in a sequential pattern.
Study NCT06074250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: 1500mg EPA +1000mg DHA daily
Study NCT06074250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Combination strain of lactobacillus and bifidobacteria
Study NCT06074250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prebiotics
Description: Dietary consult with follow-up to ensure target fiber intake is met.
Study NCT06074250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet Quality
Description: one time dietary consult at enrollment to discuss strategies to improve overall diet.
Study NCT06186388 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TEMPO iMOvifa
Description: Screening test with 28 testing points
Study NCT05937035 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Customized allogenic bone block surgery
Description: After studying the CBCT to regenerate the posterior sites of the mandible, the investigators will design CAD/CAM freeze- dried bone allograft to fit exactly on the defect morphology that the patients present. A full thickness flap will be released to have a correct access of the defects. Releasing incisions will be performed to achieve the correct closure of the flap. The sterile blocks have to fit perfectly on the defect and fixed by screws. Covered with resorbable membranes fixed with pines and suture. 4 months later, photographs, periapical xrays digital impressions and 2nd CBCTwill be performed. During the implant surgery, a bone trephine will be removed and sent into a Laboratory to make a histological study of the bone block for histomorphometry. After 3 months, second-stage surgery and healing caps will be placed if needed. Impressions will be taken 2 weeks after to perform the final crowns.
Study NCT04721327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: remote CI programming
Description: provision of CI programming provided remotely via Zoom in a 2 hour session
Study NCT05991778 — intervention group
Intervention type: DEVICE
Intervention: Bioelectrical impedance vector analysis (BIVA)
Description: BIVA is a simple, rapid, and noninvasive method, based on the principle that the flow of altering electrical current through a particular tissue differs depending on the content of water and electrolytes, used for monitoring hydratation and nutritional status in critically ill patients.
Study NCT05991778 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine analysis
Description: For regular measurement in 2-3 terms, depending on the length of hospitalization (the first measurement took place within 48 hours of admission, followed one week after admission and the last before transport from the ICU): laboratory indicators of nutritional status will also be taken (albumin, prealbumin, creatinine), inflammation (C-reactive protein, presepsin) and 25-hydroxyvitamin D level.
Study NCT05991778 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cumulative water balance
Description: Cumulative balance is the sum of daily fluid balances during hospitalization.
Study NCT05773105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab+regorafenib
Description: cadonilimab(10mg/kg, iv,Q3W,D1) + regorafenib(80mg,PO,QD,everyday)
Study NCT05988593 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: consume one bottle (30 mL) per day
Study NCT05988593 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MelaGene+
Description: consume one bottle (30 mL) per day
Study NCT04709029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone intravenous
Description: Evaluation of intravenous dexamethazone in prevention of postdural puncture headache
Study NCT04709029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone intrathecal
Description: Evaluation of intrathecal dexamethazone in prevention of postdural puncture headache
Study NCT05569421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: BGF MDI HFO
Description: Participants will receive 4 oral inhalations as a single dose - test formulation; administered during 1 treatment period.
Study NCT05569421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: BGF MDI HFA
Description: Participants will receive 4 oral inhalations as a single dose - reference formulation; administered during 2 treatment periods.
Study NCT06541912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional implant
Description: A full thickness mucoperiosteal flap was elevated under local anesthesia, osteotomy sites were prepared according to manufacturer's instructions and parallel pin was used to confirm position and angulation of osteotomy site. Conventional implant placement was done on one side.~Resonance frequency analysis instrument was used to measure Implant Stability Quotient (ISQ) and check the primary stability of the implant. The surgical wound closure was done with mattress and single interrupted sutures, using 4-0 vicryl sutures.
Study NCT06541912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UV implant
Description: A full thickness mucoperiosteal flap was elevated under local anesthesia and osteotomy sites were prepared according to manufacturer's instructions. Parallel pin was used to confirm position and angulation of osteotomy site. UV implant was activated using UV Activator2 and placed in another site.~Resonance frequency analysis instrument was used to measure Implant Stability Quotient (ISQ) and primary stability of the implant was measured. The surgical wound closure was done with mattress and single interrupted sutures, using 4-0 vicryl sutures.
Study NCT06537102 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Unilateral laparoscopic ovarian drilling
Description: Laparoscopic drilling was performed under general anesthesia as follows: 10-mm subumbilical entry and two 5-mm secondary ports in the lower part of the abdomen just above the anterior superior iliac spine. The laparoscope is introduced through the subumbilical port, and secondary ports was used for introduction of the instruments, the type of needle was an insulated unipolar needle electrode with a non-insulated distal end. We are planning to use the least thermal effective dose which is 60 J/cm3 of ovarian tissue.~The number of punctures (Np) per ovary was calculated according to the following formula: N p = 60 J/cm3/40 W × 4 s, with 3 mm diameter and 4 mm depth for each puncture using power setting of 300 W for 2-4 s. Unilateral: was done on the larger ovary.
Study NCT06537102 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bilateral laparoscopic ovarian drilling
Description: Laparoscopic drilling was performed under general anesthesia as follows: 10-mm subumbilical entry and two 5-mm secondary ports in the lower part of the abdomen just above the anterior superior iliac spine. The laparoscope is introduced through the subumbilical port, and secondary ports was used for introduction of the instruments, the type of needle was an insulated unipolar needle electrode with a non-insulated distal end. We are planning to use the least thermal effective dose which is 60 J/cm3 of ovarian tissue.~The number of punctures (Np) per ovary was calculated according to the following formula: N p = 60 J/cm3/40 W × 4 s, with 3 mm diameter and 4 mm depth for each puncture using power setting of 300 W for 2-4 s. Bilateral: Using dose adjusted according to ovarian volume.
Study NCT06430307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saussurea Involucrata Liquid Tonic
Description: This product is a single preparation of Saussurea Involucrata Liquid Tonic. It is used for rheumatoid arthritis, rheumatoid arthritis and dysmenorrhea caused by insufficient kidney yang and cold-damp stasis.
Study NCT06430307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saussurea Involucrata Liquid Tonic
Description: This product is a single preparation of Saussurea Involucrata Liquid Tonic. It is used for rheumatoid arthritis, rheumatoid arthritis and dysmenorrhea caused by insufficient kidney yang and cold-damp stasis.
Study NCT06309121 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postbiotic ABB C3
Description: A daily dose of 550 mg of the postbiotic blend ABB C3 in individual sachets for the first 3 months of the study.
Study NCT06309121 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A daily dose of 550 mg of the placebo in individual sachets for the first 3 months of the study.
Study NCT06309121 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Follow-up Postbiotic ABB C3 (Optional)
Description: Option given to all participants: a daily dose of 550 mg of the postbiotic blend ABB C3 in individual sachets for months 4 to 6 of the study.
Study NCT06309121 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Follow-up Postbiotic ABB C3 (Optional)
Description: Option given to all participants: a daily dose of 550 mg of the postbiotic blend ABB C3 in individual sachets for months 4 to 6 of the study.
Study NCT06360679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic gastric restriction and biliodigestive diversion
Description: The BariTon™ is endoscopically implanted and retrieved once treatment is completed
Study NCT05496101 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intraoperative CLI + FAR LightPath imaging
Description: Imaging System: The LightPath Imaging System is an in vitro diagnostic device which has CE mark in Europe, in line with In Vitro Diagnostic Medical Devices 98/79/EC (post marketing study).~Radiopharmaceutical:~18F-FDG is a routinely used Positron Emission Tomography (PET) / Computed Tomography (CT) radiopharmaceutical
Study NCT06463847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: In this study, three dose groups are preset, which are low-dose group: 5×10\^6 cells/2.5mL; medium-dose group: 1×10\^7 cells/2.5mL; high-dose group: 2×10\^7cells/2.5mL, 9 to 18 subjects will be recruited, and will be sequential from the low-dose group to the high-dose group according to the 3+3 dose escalation principle. At least 3 subjects are enrolled in each group for the safety and tolerability test of single administration. After the last subject in each dose group completes the DLT observation period, the sponsor and the researcher jointly confirm the safety tolerance of the subjects in the previous dose group, and only after the safe tolerance is determined can the subjects enter the next dose group, so as to evaluate the safety and tolerance of human umbilical cord mesenchymal stem cell injection in the treatment of knee osteoarthritis. Recommend appropriate cell therapy dose (RP2D) for Phase II clinical trials.
Study NCT06197139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-XT117
Description: \[177Lu\]Lu-XT117 is a radiopharmaceutical therapy in which an beta emitter, Lu-177, is conjugated to XT117. Patients will receive \[177Lu\]Lu-XT117 administration at an interval of 6 weeks between each dose.
Study NCT04790253 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic cranial irradiation
Description: Prophylactic cranial irradiation (PCI) is a technique used to combat the occurrence of metastasis to the brain in highly aggressive cancers that commonly metastasize to brain, most notably small-cell lung cancer.
Study NCT05036642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compliant Passive Arm Support
Description: The device is a mechanical device that consists of two linkages, elastic bands, a commercial posture brace, and a hook-and-loop fastener. The design of the device, with several compliant elements, ensures that one device fits many without joint alignment concerns. No motors or other actuators add energy into the system, meaning that it is stable.
Study NCT04872686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.6% PVP-I oral and nasal spray to moderately ill COVID-19 positive patient
Description: Number of participants 768 COVID-19 positive, moderately ill admitted patient who will receive intervention~Step 1: Enrollment of the study populations by applying inclusion and exclusion criteria Step 2: Randomization to allocate experimental and controlled group by using table of random number Step 3: Application of 0.6% PVP-I spray to experimental group and distilled water to control group Step 4: Follow up (waiting for 2-5 minutes) Step 5: Collection of nasopharyngeal and oropharyngealsawab for RT-PCR test for both group Step 6: Observation of the patients for 30 minutes for possible early adverse effects (if any) and subsequent management (if needed).~Step 7: Analysis data collection, data processing and analysis by using SPSS software.
Study NCT05365022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ROSA® System Robotic Assisted Knee Prosthetic Surgery
Description: Robotic Assisted Knee Prosthetic Surgery using ROSA® (Zimmer-Biomet) System
Study NCT05775536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 500Mg Tab
Description: Dose: 1 tablet per day starting from visit 2 until visit 3, intake in the evening
Study NCT05775536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dr. Böhm® Omega 3 complex 870 mg
Description: Dose: 2 tablets per day starting from visit 2 until visit 3, intake in the evening
Study NCT06248073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: on-line self-management training
Description: To encourage adherence to the home program among early-stage Parkinson's disease participants, the investigators have developed various self-management topics, including medication adherence and exercise benefits. The home program is categorized into two dimensions: daily function and exercise. The investigators will provides participants with detailed guidelines to ensure safe execution of the program independently.
Study NCT06248073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: onsite task-related training
Description: Participants will receive interventions at Chang Gung Memorial Hospital. A certified occupational therapist will conduct the interventions. These sessions will involve functional tasks tailored to each participant's skill level, with two to four varied tasks per session. Additionally, participants will be given booklets to guide them in self-managing similar exercises at home, mirroring the home program of the self-management group.
Study NCT04675528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP107(Oral paclitaxel)
Description: DHP107 200 mg/m\^2 orally twice daily on Day 1, 8, and 15 in every 28 days (On food effect study day, DHP107 200 mg/m\^2 orally once daily on Day 1, 8 of Cycle 1 with fasted or fed condition according to the assigned sequence)
Study NCT06682949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: Participants, their parent, and a researcher will review the participants actigraphy data from the two week baseline period. They will discuss sleep patterns and behaviors related to sleep. The researcher will prescribe a sleep prescription that includes set sleep and wake times and stimulus control. Participants will adhere to the sleep prescription for two weeks.
Study NCT06682949 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Daytime Routine
Description: Participant, their parent, and researcher will meet to discuss daily routines for the child and family. They will collaborate to choose one behavioral routine to modify for the following two weeks.
Study NCT06702176 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EXOPULSE MOLLII SUIT active
Description: Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more. EXOPULSE Mollii suit consists of transcutaneous stimulation of several muscles by means of a feeble electric current (i.e., low frequency \~20 Hz, low-intensity 2mA), aiming to reduce pain. This treatment method theoretical background primarily refers to the theory of gate control. Based on this theory, the stimulation of large proprioceptive fibers would inhibit the nociceptive information transmitted by small fibers.
Study NCT06702176 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EXOPULSE MOLLII SUIT (sham)
Description: It consists of applying the same parameters used for the active session (low frequency: 20 Hz; current intensity: 2 mA; pulse width ranging from 25 to 175 µs) but for a shorter duration of time (1 minute).
Study NCT06701760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Lactate
Description: sodium lactate
Study NCT06701760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: infusion of sodium chloride
Study NCT06701110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [U-14C] WX-081
Description: A single oral dose of approximately 450 mg (100 μCi) of \[U-14C\] WX-081 will be administered to healthy male volunteers. The study will involve pharmacokinetic assessments, including metabolism, mass balance, and excretion pathways, through the collection of biological samples such as blood, plasma, urine, and feces.
Study NCT05523310 — intervention group
Intervention type: OTHER
Intervention: Daily questionnaire
Description: All patients will be asked to complete a daily questionnaire regarding their migraine, medications, and prodromal symptoms during that day
Study NCT06703268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 10 mg
Description: HSK7653 10 mg Q2W
Study NCT06703268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daily DPP-4 inhibitor
Description: Daily DPP-4 inhibitor
Study NCT06703931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measures performed on all subjects
Description: In intensive care Medics will use a reference medical device and Thermodiag®. Simultaneous and synchronised measurements will be taken every minute.
Study NCT06702969 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra oral scanner
Description: Immediate implant placement with customized healing abutment and after three months placement all ceramic crown by digital impression using intra oral scanner
Study NCT06702969 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: impression analog
Description: Immediate implant placement with customized healing abutment and after three months placement of all ceramic crowns by conventional impression
Study NCT06702878 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: nasal antimicrobial photodisinfection therapy
Description: Application of NF-031 solution (methylene blue 0.01% USP (methylthioninium chloride) and 0.25% chlorhexidine gluconate) in the nares followed by 2-minutes of light with nasal illuminators. The application is repeated a second time for total treatment time of 5-minutes.
Study NCT06703632 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood sampling
Description: PreveCol test based on blood sampling
Study NCT06703632 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Survey using a questionnaire.
Description: Preference questionnaire for colorectal cancer screening methods
Study NCT06703632 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Survey using a questionnaire.
Description: PREMs for colorectal cancer screening programme